Globeflex Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Globeflex Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.41M	Sell	112,672 -105,167	-48%	-$3.24M	0.56%	59
2026 Q1	$5.89M	Hold	217,839	–	–	0.89%	32
2025 Q4	$9.33M	Buy	217,839 +209	+0.1%	+$7.88K	1.43%	7
2025 Q3	$6.17M	Buy	217,630 +50,115	+30%	+$1.5M	0.95%	24
2025 Q2	$3.14M	Buy	167,515 +115,220	+220%	+$2.18M	0.26%	95
2025 Q1	$941K	Hold	52,295	–	–	0.09%	174
2024 Q4	$880K	Buy	52,295 +43,095	+468%	+$827K	0.07%	203
2024 Q3	$149K	Buy	+9,200	New	+$108K	0.01%	341
2016 Q3	–	Sell	-33,953	Closed	-$757K	–	536
2016 Q2	$757K	Sell	33,953 -11,000	-24%	-$274K	0.21%	186
2016 Q1	$935K	Buy	+44,953	New	+$1.11M	0.25%	142

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Globeflex Capital's RIGL Position: Q2 2026 in Review

Globeflex Capital reduced its Rigel Pharmaceuticals (RIGL) stake by 48% in Q2 2026, selling an estimated $3.24M and leaving 112,672 shares worth $4.41M. The position accounts for 0.56% of the portfolio, ranked #59.

Globeflex Capital first reported a position in RIGL in Q1 2016 and has held it in 10 quarters since. The position peaked at $9.33M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Globeflex Capital held 112,672 shares of Rigel Pharmaceuticals worth $4.41M as of Q2 2026.
Globeflex Capital sold 105,167 Rigel Pharmaceuticals shares in Q2 2026, an estimated $3.24M.
Rigel Pharmaceuticals made up 0.56% of Globeflex Capital's portfolio in Q2 2026, its #59 holding.
Globeflex Capital first reported a position in Rigel Pharmaceuticals in Q1 2016 and has held it in 10 quarters since.
Globeflex Capital's Rigel Pharmaceuticals position peaked at $9.33M in Q4 2025.
156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.